Alere (ALRPRB.PFD) EPS (Basic) : $0.00 (TTM As of Jun. 2017)

View and export this data going back to 2008. Start your Free Trial

What is Alere EPS (Basic)?

Alere's basic earnings per share (Basic EPS) for the three months ended in Jun. 2017 was $0.00. Its basic earnings per share (Basic EPS) for the trailing twelve months (TTM) ended in Jun. 2017 was $0.00.

Alere's EPS (Diluted) for the three months ended in Jun. 2017 was $0.00. Its EPS (Diluted) for the trailing twelve months (TTM) ended in Jun. 2017 was $0.00.

Alere's EPS without NRI for the three months ended in Jun. 2017 was $0.00. Its EPS without NRIearnings per share without non-recurring items for the trailing twelve months (TTM) ended in Jun. 2017 was 0.00.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EPS without NRI Growth Rate using EPS without NRI data.

Alere EPS (Basic) Historical Data

The historical data trend for Alere's EPS (Basic) can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Alere EPS (Basic) Chart

Alere Annual Data

Trend

Dec07

Dec08

Dec09

Dec10

Dec11

Dec12

Dec13

Dec14

Dec15

Dec16

EPS (Basic)

Get a 7-Day Free Trial

Alere Quarterly Data
	Sep12	Dec12	Mar13	Jun13	Sep13	Dec13	Mar14	Jun14	Sep14	Dec14	Mar15	Jun15	Sep15	Dec15	Mar16	Jun16	Sep16	Dec16	Mar17	Jun17
EPS (Basic)	Get a 7-Day Free Trial															-	-	-	-	-

Alere EPS (Basic) Calculation

EPS (Basic) is a rough measurement of the amount of a company's profit that can be allocated to one share of its stock. Basic earnings per share (EPS) do not factor in the dilutive effects on convertible securities.

Alere's Basic EPS for the fiscal year that ended in Dec. 2016 is calculated as

Basic EPS (A: Dec. 2016 )	=	(Net Income	-	Preferred Dividends)	/	Shares Outstanding (Basic Average)
	=	(-137.619	-	21.35)	/	0
	=

Alere's Basic EPS for the quarter that ended in Jun. 2017 is calculated as

Basic EPS (Q: Jun. 2017 )	=	(Net Income	-	Preferred Dividends)	/	Shares Outstanding (Basic Average)
	=	(-93.068	-	5.308)	/	0
	=

EPS (Basic) for the trailing twelve months (TTM) ended in Jun. 2017 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.00

Alere (NYSE:ALRPRB.PFD) EPS (Basic) Explanation

EPS is the single most important variable used by Wall Street in determining the earnings power of a company. But investors need to be aware that Earnings per Share can be easily manipulated by adjusting depreciation and amortization rate or non-recurring items. That's why GuruFocus lists EPS without NRI, which better reflects the company's underlying performance.

Be Aware

Compared with Earnings per share, a company's cash flow is better indicator of the company's earnings power.

If a company's earnings per share is less than cash flow per share over long term, investors need to be cautious and find out why.

Alere EPS (Basic) Related Terms

Thank you for viewing the detailed overview of Alere's EPS (Basic) provided by GuruFocus.com. Please click on the following links to see related term pages.

Alere (ALRPRB.PFD) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » Alere Inc (NYSE:ALRPRB.PFD) » Definitions » EPS (Basic)

Comparable Companies

Traded in Other Exchanges

N/A

Address

Website

http://www.alere.com

Alere, Inc. develops rapid point-of-care diagnostic devices in cardiology, infectious disease, toxicology, diabetes, oncology, and women's health. North America accounts for the largest portion of the firm's revenue (55%), followed by Europe (19%), Asia-Pacific (14%), and the rest of the world (12%). Alere's headquarters are in Waltham, Massachusetts.

Executives

John Bridgen	officer: Sr VP, Business Development	51 SAWYER ROAD, C/O INVERNESS MEDICAL INNOVATIONS INC, WALTHAM MA 02453
Geoffrey S Ginsburg	director	51 SAWYER ROAD, SUITE 200, WALTHAM MA 02453
Renuka Uppaluri	officer: Senior VP, Global R&D	51 SAWYER ROAD, SUITE 200, WALTHAM MA 02453
Mark Gladwell	officer: Senior VP, Global Operations	51 SAWYER ROAD, SUITE 200, WALTHAM MA 02453
Gregg J Powers	director	C/O QUANTUM CORPORATION, 224 AIRPORT PARKWAY SUITE 300, SAN JOSE CA 95110
Jonathan Wygant	officer: VP, Controller, CAO	3750 TORREY VIEW COURT, SAN DIEGO X1 92130
Thomas Mckillop	director	51 SAWYER ROAD, SUITE 200, WALTHAM MA 02453
Melissa Guerdan	officer: SVP, Global Quality & Reg.	51 SAWYER ROAD, SUITE 200, WALTHAM MA 02453
Daniella Cramp	officer: Global Pres., Cardiometabolic	51 SAWYER ROAD, SUITE 200, WALTHAM MA 02453
Sanjay Malkani	officer: Global Pres., Toxicology	51 SAWYER ROAD, SUITE 200, WALTHAM MA 02453
James Jr. Roosevelt	director	51 SAWYER ROAD, SUITE 200, HOPKINTON MA 02453
Robert Bernard Hargadon	officer: SVP, Global Human Resources	4327 LAKE WASHINGTON BLVD NE #6208, KIRKLAND WA 98033
John F Levy	director	C/O INNVERNESS MEDICAL INNOVATIONS, INC., 51 SAWYER ROAD, WALTHAM MA 02453
John Quelch	director	C/O INVERNESS MEDICAL INNOVATIONS INC, 51 SAWYER RD, WALTHAM MA 02453
Carol R Goldberg	director	C/O INVERNESS MEDICAL INNOVATIONS INC, 51 SAWYERS RD, WALTHAM MA 02453